BiotechTube

sapropterin dihydrochloride

Phase 3Completed
1 views this week 0 watching💤 Quiet
Interest: 37/100
37
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Phenylketonuria

Conditions

Phenylketonuria

Trial Timeline

Feb 1, 2009 → Sep 14, 2018

NCT ID
NCT00838435

About sapropterin dihydrochloride

sapropterin dihydrochloride is a phase 3 stage product being developed by BioMarin Pharmaceutical for Phenylketonuria. The current trial status is completed. This product is registered under clinical trial identifier NCT00838435. Target conditions include Phenylketonuria.

What happened to similar drugs?

7 of 20 similar drugs in Phenylketonuria were approved

Approved (7) Terminated (1) Active (12)
❌SYNB1934v1 + PlaceboSynlogicPhase 3
🔄Kuvan®MerckPhase 3
✅Kuvan®MerckApproved
🔄Sapropterin dihydrochloride + PlaceboBioMarin PharmaceuticalPhase 3
🔄BMN165 20mg/day + BMN165 40mg/day + PlaceboBioMarin PharmaceuticalPhase 3
✅saproterin dihydrochlorideBioMarin PharmaceuticalApproved
✅Pegvaliase + MethotrexateBioMarin PharmaceuticalApproved

Hype Score Breakdown

Clinical
17
Activity
8
Company
12
Novelty
0
Community
0

Clinical Trials (9)

NCT IDPhaseStatus
NCT00484991Pre-clinicalCompleted
NCT01274026Pre-clinicalCompleted
NCT01141595Pre-clinicalCompleted
NCT00838435Phase 3Completed
NCT00445978Phase 2Completed
NCT00403494Phase 2Completed
NCT00332189Phase 3Completed
NCT00225615Phase 3Completed
NCT00104260Phase 2Completed

Competing Products

20 competing products in Phenylketonuria

See all competitors
ProductCompanyStageHype Score
mRNA-3210ModernaPhase 2
0
SYNB1934v1 + PlaceboSynlogicPhase 3
22
SYNB1618 + PlaceboSynlogicPhase 1/2
22
SYNB1618 + SYNB1934SynlogicPhase 2
25
Kuvan®MerckPhase 3
40
Kuvan®MerckApproved
43
SAR444836SanofiPhase 1/2
36
KuvanBioMarin PharmaceuticalPre-clinical
15
rAvPAL-PEGBioMarin PharmaceuticalPhase 2
32
rAvPAL-PEGBioMarin PharmaceuticalPhase 2
32
Sapropterin (Kuvan)BioMarin PharmaceuticalPre-clinical
23
BMN 165 (rAvPAL-PEG)BioMarin PharmaceuticalPhase 2
32
BMN 307BioMarin PharmaceuticalPhase 1/2
33
SapropterinBioMarin PharmaceuticalPre-clinical
23
Sapropterin dihydrochloride + PlaceboBioMarin PharmaceuticalPhase 3
37
BMN165 20mg/day + BMN165 40mg/day + PlaceboBioMarin PharmaceuticalPhase 3
37
saproterin dihydrochlorideBioMarin PharmaceuticalApproved
40
sapropterin dihydrochloride + Moxifloxacin + Moxifloxacin placeboBioMarin PharmaceuticalPhase 1
26
PegvaliaseBioMarin PharmaceuticalPre-clinical
30
PegvaliaseBioMarin PharmaceuticalPre-clinical
23